NASDAQ:LMAT - LeMaitre Vascular Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.04 -0.40 (-1.13 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$35.44
Today's Range$34.92 - $35.57
52-Week Range$26.37 - $41.28
Volume120,400 shs
Average Volume150,638 shs
Market Capitalization$695.25 million
P/E Ratio40.74
Dividend Yield0.78%
Beta0.57
LeMaitre Vascular logoLeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LMAT
CUSIPN/A
Phone781-221-2266

Debt

Debt-to-Equity RatioN/A
Current Ratio6.65
Quick Ratio4.92

Price-To-Earnings

Trailing P/E Ratio40.74
Forward P/E Ratio32.15
P/E Growth2.21

Sales & Book Value

Annual Sales$100.87 million
Price / Sales6.71
Cash Flow$1.0725 per share
Price / Cash32.67
Book Value$5.70 per share
Price / Book6.15

Profitability

EPS (Most Recent Fiscal Year)$0.86
Net Income$17.17 million
Net Margins17.34%
Return on Equity16.66%
Return on Assets14.57%

Miscellaneous

Employees423
Outstanding Shares19,310,000

LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Monday, April 23rd. Shareholders of record on Tuesday, May 22nd will be paid a dividend of $0.07 per share on Thursday, June 7th. This represents a $0.28 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Monday, May 21st. View LeMaitre Vascular's Dividend History.

How will LeMaitre Vascular's stock buyback program work?

LeMaitre Vascular announced that its board has approved a share buyback plan on Friday, July 28th 2017, which allows the company to buyback $7,500,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular Inc (NASDAQ:LMAT) posted its earnings results on Wednesday, April, 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.02. The medical instruments supplier earned $25.99 million during the quarter, compared to analyst estimates of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.16 earnings per share. View LeMaitre Vascular's Earnings History.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.05-1.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98. The company issued revenue guidance of $106-109 million, compared to the consensus revenue estimate of $111.05 million.LeMaitre Vascular also updated its Q2 guidance to $0.41-0.43 EPS.

What price target have analysts set for LMAT?

5 brokerages have issued twelve-month target prices for LeMaitre Vascular's stock. Their predictions range from $33.00 to $40.00. On average, they expect LeMaitre Vascular's stock price to reach $35.80 in the next year. View Analyst Ratings for LeMaitre Vascular.

Who are some of LeMaitre Vascular's key competitors?

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the folowing people:
  • Mr. George W. LeMaitre, Chairman & CEO (Age 53)
  • Mr. David B. Roberts, Pres and Director (Age 54)
  • Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 53)
  • Dr. George D. LeMaitre M.D., FACS, Founder and Chairman of Scientific Advisory Board (Age 84)
  • Mr. Trent G. Kamke, Sr. VP of Operations (Age 47)

Has LeMaitre Vascular been receiving favorable news coverage?

Media stories about LMAT stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LeMaitre Vascular earned a media sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 46.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.08%), Dimensional Fund Advisors LP (5.20%), Epoch Investment Partners Inc. (3.99%), Thomson Horstmann & Bryant Inc. (1.78%), Allianz Asset Management GmbH (1.70%) and Allianz Asset Management GmbH (1.70%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Biondo Investment Advisors LLC, Fiera Capital Corp and Thomson Horstmann & Bryant Inc.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski, Peter R Gebauer and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sensato Investors LLC, King Luther Capital Management Corp, BlackRock Inc., WINTON GROUP Ltd, Epoch Investment Partners Inc., Campbell & CO Investment Adviser LLC and Dupont Capital Management Corp. View Insider Buying and Selling for LeMaitre Vascular.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $35.04.

How big of a company is LeMaitre Vascular?

LeMaitre Vascular has a market capitalization of $695.25 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.


MarketBeat Community Rating for LeMaitre Vascular (LMAT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.